CP 55,940

Discontinued Product

0949 has been discontinued.
View all Non-selective Cannabinoid Receptor Agonists products.
CP 55,940 | CAS No. 83002-04-4 | Non-selective Cannabinoid Receptor Agonists
1 Image
Description: Potent and non-selective CB agonist

Chemical Name: (-)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol

Purity: ≥98%

Product Details
Citations (54)
Reviews

Biological Activity

Cannabinoid agonist which is considerably more potent than Δ9-THC in both behavioral tests and receptor binding assays. Displays high and roughly equal affinity for both central and peripheral cannabinoid receptors (Ki = 0.6 - 5.0 and 0.7 - 2.6 nM at CB1 and CB2 respectively; EC50 values are 0.2, 0.3 and 5 nM at CB1, CB2 and GRP55 respectively).

Technical Data

M.Wt:
376.58
Formula:
C24H40O3
Solubility:
Soluble to 100 mM in ethanol and to 100 mM in DMSO
Purity:
≥98%
Storage:
Store at -20°C
CAS No:
83002-04-4

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Additional Information

Licensing Caveats:
Sold for research purposes under agreement from Pfizer Inc.

Product Datasheets

Or select another batch:
Reconstitution Calculator
Molarity Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Molarity Calculator

=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Citations for CP 55,940

The citations listed below are publications that use Tocris products. Selected citations for CP 55,940 include:

54 Citations: Showing 1 - 10

  1. Activity in nodose ganglia neurons after treatment with CP 55,940 and cholecystokinin.
    Authors: Johnston Et al.
    Physiol Rep  2018;6:e13927
  2. Structure-Based Identification of Potent Natural Product Chemotypes as Cannabinoid Receptor 1 Inverse Agonists.
    Authors: Pandey Et al.
    Molecules  2018;23
  3. Characterization of structurally novel G protein biased CB1 agonists: implications for drug development.
    Authors: Ford
    Pharmacol Res  2017;125:161
  4. Regulation of divalent metal transporter-1 by serine phosphorylation.
    Authors: Seo Et al.
    Biochem J  2016;473:4243
  5. Cannabinoid receptor-specific mechanisms to alleviate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation.
    Authors: Vincent Et al.
    Haematologica  2016;101:566
  6. (4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride (LDK1229): a new cannabinoid CB1 receptor inverse agonist from the class of benzhydryl piperazine analogs.
    Authors: Mahmoud Et al.
    Mol Pharmacol  2015;87:197
  7. Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist.
    Authors: Presley Et al.
    Eur J Pharmacol  2015;3:e00159
  8. Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
    Authors: Mounsey Et al.
    Pharmacol Res Perspect  2015;273:36
  9. Flavanones from Miconia prasina.
    Authors: Tarawneh Et al.
    Phytochem Lett  2014;7:130
  10. Potential upstream regulators of cannabinoid receptor 1 signaling in prostate cancer: a Bayesian network analysis of data from a tissue microarray.
    Authors: Häggström Et al.
    J Biol Chem  2014;74:1107
  11. The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys.
    Authors: Hruba and McMahon
    Br J Pharmacol  2014;727:35
  12. Prefrontal deficits in a murine model overexpressing the down syndrome candidate gene dyrk1a.
    Authors: Thomazeau Et al.
    J Neurosci  2014;34:1138
  13. Analgesic effect of a mixed T-type channel inhibitor/CB2 receptor agonist.
    Authors: Gadotti Et al.
    Mol Pain  2013;9:32
  14. CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity.
    Authors: Baillie Et al.
    Mol Pharmacol  2013;83:322
  15. Long-term CB1 receptor blockade enhances vulnerability to anxiogenic-like effects of cannabinoids.
    Authors: Tambaro Et al.
    Neuropharmacology  2013;70:268
  16. Mastering tricyclic ring systems for desirable functional cannabinoid activity.
    Authors: Petrov Et al.
    Eur J Med Chem  2013;69:881
  17. CB1 and CB2 receptors are novel molecular targets for tamox. and 4OH-Tamoxifen.
    Authors: Prather Et al.
    Biochem Biophys Res Commun  2013;441:339
  18. Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB1 receptors: implications for schizophrenia.
    Authors: Seillier Et al.
    Eur J Pharmacol  2013;38:1816
  19. Novel insights into CB1 cannabinoid receptor signaling: a key interaction identified between the extracellular-3 loop and transmembrane helix 2.
    Authors: Marcu Et al.
    J Pharmacol Exp Ther  2013;345:189
  20. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.
    Authors: Rajasekaran Et al.
    Toxicol Appl Pharmacol  2013;269:100
  21. Real-time characterization of cannabinoid receptor 1 (CB1 ) allosteric modulators reveals novel mechanism of action.
    Authors: Cawston Et al.
    Br J Pharmacol  2013;170:893
  22. Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors.
    Authors: Marini Et al.
    Br J Pharmacol  2013;169:887
  23. Working memory- and anxiety-related behavioral effects of repeated nicotine as a stressor: the role of cannabinoid receptors.
    Authors: Hayase
    BMC Neurosci  2013;14:20
  24. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.
    Authors: Brents Et al.
    Biochem Pharmacol  2012;83:952
  25. CB1 receptor autoradiographic characterization of the individual differences in approach and avoidance motivation.
    Authors: Laricchiuta Et al.
    PLoS One  2012;7:e42111
  26. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
    Authors: Chimalakonda Et al.
    Drug Metab Dispos  2012;40:2174
  27. AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor.
    Authors: Bolognini Et al.
    Br J Pharmacol  2012;165:2561
  28. A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury.
    Authors: Horváth Et al.
    J Physiol  2012;165:2462
  29. Mouse models for studying pain in sickle disease: effects of strain, age, and acuteness.
    Authors: Cain Et al.
    Br J Haematol  2012;156:535
  30. Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands.
    Authors: You Et al.
    Mol Pain  2011;7:89
  31. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity.
    Authors: Brents Et al.
    PLoS One  2011;6:e21917
  32. Convulsant doses of a DA D1 receptor agonist result in Erk-dependent increases in Zif268 and Arc/Arg3.1 expression in mouse dentate gyrus.
    Authors: Gangarossa Et al.
    PLoS One  2011;6:e19415
  33. Cannabinoids attenuate hippocampal γ oscillations by suppressing excitatory synaptic input onto CA3 pyramidal neurons and fast spiking basket cells.
    Authors: Holderith Et al.
    Br J Pharmacol  2011;589:4921
  34. Symptom-relieving and neuroprotective effects of the phytocannabinoid △9-THCV in animal models of Parkinson's disease.
    Authors: García Et al.
    J Cell Mol Med  2011;163:1495
  35. A putative 'pre-nervous' endocannabinoid system in early echinoderm development.
    Authors: Buznikov Et al.
    J Biol Chem  2010;32:43101
  36. Location, structure, and dynamics of the synthetic cannabinoid ligand CP-55,940 in lipid bilayers.
    Authors: Kimura Et al.
    Biophys J  2009;96:4916
  37. Genetic and pharmacological manipulations of the CB(1) receptor alter ethanol preference and dependence in ethanol preferring and nonpreferring mice.
    Authors: Vinod Et al.
    Synapse  2008;62:574
  38. Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling.
    Authors: Georgieva Et al.
    Neuropsychopharmacology  2008;581:19
  39. Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction.
    Authors: Kapur Et al.
    J Pharmacol Exp Ther  2008;325:341
  40. MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models.
    Authors: Naguib Et al.
    Br J Pharmacol  2008;155:1104
  41. Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs.
    Authors: Giannini Et al.
    Prostate  2008;12:2381
  42. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
    Authors: Pertwee Et al.
    Br J Pharmacol  2007;150:586
  43. S-nitrosothiols modulate G protein-coupled receptor signaling in a reversible and highly receptor-specific manner.
    Authors: Kokkola Et al.
    BMC Cell Biol  2005;6:21
  44. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation.
    Authors: Ehrhart Et al.
    J Neuroinflammation  2005;2:29
  45. Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.
    Authors: Thomas Et al.
    Br J Pharmacol  2005;146:917
  46. Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor.
    Authors: Savinainen Et al.
    Br J Pharmacol  2005;145:636
  47. The endocannabinoid 2-arachidonylglycerol decreases the immunological activation of Guinea pig mast cells: involvement of nitric oxide and eicosanoids.
    Authors: Vannacci Et al.
    J Pharmacol Exp Ther  2004;311:256
  48. Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716.
    Authors: Hilairet Et al.
    Exp Neurol  2003;278:23731
  49. An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors.
    Authors: Savinainen Et al.
    Br J Pharmacol  2003;140:1451
  50. Cannabinoid receptor-independent inhibition by cannabinoid agonists of the peripheral 5-HT3 receptor-mediated von Bezold-Jarisch reflex.
    Authors: Godlewski Et al.
    Br J Pharmacol  2003;138:767
  51. Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site.
    Authors: Barann Et al.
    Br J Pharmacol  2002;137:589
  52. Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens.
    Authors: Christopoulos Et al.
    Br J Pharmacol  2001;132:1281
  53. The endogenous cannabinoid agonist, anandamide stimulates sensory nerves in guinea-pig airways.
    Authors: Tucker Et al.
    Br J Pharmacol  2001;132:1127
  54. The actions of some cannabinoid receptor ligands in the rat isolated mesenteric artery.
    Authors: White and Hiley
    Br J Pharmacol  1998;125:533

FAQs

No product specific FAQs exist for this product, however you may

View all Small Molecule FAQs

Reviews for CP 55,940

There are currently no reviews for this product. Be the first to review CP 55,940 and earn rewards!

Have you used CP 55,940?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review
Tocris Bioscience is the leading supplier of novel and exclusive tools for life science research with over 30 years' experience in the industry. Tocris is a Bio-Techne brand.